相关实验视频
Updated: Jul 16, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.8K
维生素B6通过调节NHE1表达而对多克索鲁比诱导的心脏毒性的保护作用
Rui-Li Sun1,2, Huan-Huan Wang2, Zi-Chen Gui3
1Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Key Laboratory of Tumor Microenvironment and Immunotherapy, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China.
Journal of biochemical and molecular toxicology
|September 13, 2023
概括
维生素B6 (VitB6) 补充剂通过减少氧化应激和亡来减轻多克索鲁比 (DOX) 引起的心脏毒性. 这种保护作用可能涉及到心脏中Na+/H+交换器 (NHE1) 的下调.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 多克索鲁比 (DOX) 是一种有效的化疗剂,但会引起心脏毒性.
- Na+/H+交换器1 (NHE1) 抑制和活性氧物种 (ROS) 减少与心力衰竭的减少有关.
- 维生素B6 (VitB6) 在抗氧化机制中起作用.
研究的目的:
- 研究维生素B6 (VitB6) 对多克索鲁比 (DOX) 诱导的心脏毒性的心脏保护作用.
- 确定Na+/H+交换器1 (NHE1) 在VitB6的保护机制中的潜在参与.
主要方法:
- 超声波心脏图分析以评估心脏功能.
- 使用血素和素 (HE) 和马森三色染色的组织病理学检查.
- 生物化学试验测量血清甲酸 (MDA) 和超氧化物溶解酶 (SOD) 的水平.
- 对亡相关蛋白质的分析,包括Bcl-2-关联X蛋白/B细胞淋巴瘤-2的比率.
主要成果:
- 维生素B6补充剂显著缓解了DOX诱导的心脏毒性,通过改善心脏功能和组织病理学证实了这一点.
- 维生素B6表现出显著的抗氧化作用,由MDA降低和SOD水平增加表明.
- 维生素B6表现出抗亡作用,由降低Bcl-2-关联X蛋白/B细胞淋巴瘤-2比率显示.
- 补充VitB6与减少NHE1表达有关.
结论:
- 维生素B6 (VitB6) 补充剂可以防止多克索鲁比 (DOX) 引起的心脏毒性.
- 维生素B6通过抗氧化和抗亡机制发挥其心脏保护作用.
- 降低Na+/H+交换器1 (NHE1) 的调节可能与VitB6对DOX诱导的心脏毒性的有益作用有关.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Heart Failure Drugs: Inotropic Agents
617
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
617
Cardiomyopathy VI: Nursing Management
13
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
13
Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460

